New theory of cerebral amine function and its clinical application

Antimanic potency of typical neuroleptic drugs and affinity for dopamine D2 and serotonin 5-HT2A receptors--a new analysis of data from the archives and implications for improved antimanic treatments

Datasets of antimanic potency ratings and receptor-binding affinities [inhibition constants (K(i))] at dopamine D2 and serotonin 5-HT2A brain receptors were accessed from published literature for a large series (n = 24) of typical neuroleptic drugs, many of which are now obsolete and unobtainable. There was a strong positive association between antimanic potency and affinity for D2 receptors, in support of a 'dopamine-blockade hypothesis' of antimanic drug action. Taking the series of neuroleptics as a whole, there was no association between antimanic potency and affinity for 5-HT2A receptors. Despite this, within a subsample of typical neuroleptics with low affinity for D2 receptors resembling new generation atypical antipsychotics, a positive association between antimanic potency and affinity for 5-HT2A receptors emerged. This suggests that blockade of brain 5-HT2A receptors plays at least a subsidiary role in the antimanic effects of some typical neuroleptics. Other considerations also suggest that combining drugs to achieve high affinity for and blockade of both dopamine D2 receptors and serotonin 5-HT2A receptors, possibly with additional direct or indirect stimulation of postsynaptic 5-HT1A receptors, might maximize antimanic efficacy.

Tryptamine induces tryptophanyl-tRNA synthetase-mediated neurodegeneration with neurofibrillary tangles in human cell and mouse models

The neuropathological hallmarks of Alzheimer's disease (AD) and other taupathies include neurofibrillary tangles and plaques. Despite the fact that only 2-10% of AD cases are associated with genetic mutations, no nontransgenic or metabolic models have been generated to date. The findings of tryptophanyl-tRNA synthetase (TrpRS) in plaques of the AD brain were reported recently by the authors. Here it is shown that expression of cytoplasmic-TrpRS is inversely correlated with neurofibrillary degeneration, whereas a nonionic detergent-insoluble presumably aggregated TrpRS is simultaneously accumulated in human cells treated by tryptamine, a metabolic tryptophan analog that acts as a competitive inhibitor of TrpRS. TrpRSN- terminal peptide self-assembles in double-helical fibrils in vitro. Herein, tryptamine causes neuropathy characterized by motor and behavioral deficits, hippocampal neuronal loss, neurofibrillary tangles, amyloidosis, and glucose decrease in mice. Tryptamine induced the formation of helical fibrillary tangles in both hippocampal neurons and glia. Taken together with the authors' previous findings of tryptamine-induced nephrotoxicity and filamentous tangle formation in kidney cells, the authors' data indicates a general role of tryptamine in cell degeneration and loss. It is concluded that tryptamine as a component of a normal diet can induce neurodegeneration at the concentrations, which might be consumed along with food. Tryptophan-dependent tRNAtrp aminoacylation catalyzed by TrpRS can be inhibited by its substrate tryptophan at physiological concentrations was demonstrated. These findings indicate that the dietary supplementation with tryptophan as a tryptamine competitor may not counteract the deleterious influence of tryptamine. The pivotal role of TrpRS in protecting against neurodegeneration is suggested, providing an insight into the pathogenesis and a possible treatment of neurodegenerative diseases.

The Long-Term Effects of Steroid Contraceptives

The Twelfth Oliver Bird Lecture was delivered by Professor Richard Doll, Regius Professor of Medicine in the University of Oxford, at the London School of Hygiene and Tropical Medicine on 19th March 1970. This was the last lecture to be given under the auspices of the Oliver Bird Trust, an account of which starts on page 359. Professor Doll was formerly Director of the MRC Unit of Medical Statistics, in which capacity he had exceptional experience in assessing the significance of changes in the incidences of abnormal conditions. The subject of his lecture was therefore highly appropriate to his special knowledge, as well as to current controversy and to the series of Oliver Bird lectures. The Journal of Biosocial Science is glad to publish this authoritative exposition of a most important problem.

Trace amines: identification of a family of mammalian G protein-coupled receptors

Tyramine, beta-phenylethylamine, tryptamine, and octopamine are biogenic amines present in trace levels in mammalian nervous systems. Although some "trace amines" have clearly defined roles as neurotransmitters in invertebrates, the extent to which they function as true neurotransmitters in vertebrates has remained speculative. Using a degenerate PCR approach, we have identified 15 G protein-coupled receptors (GPCR) from human and rodent tissues. Together with the orphan receptor PNR, these receptors form a subfamily of rhodopsin GPCRs distinct from, but related to the classical biogenic amine receptors. We have demonstrated that two of these receptors bind and/or are activated by trace amines. The cloning of mammalian GPCRs for trace amines supports a role for trace amines as neurotransmitters in vertebrates. Three of the four human receptors from this family are present in the amygdala, possibly linking trace amine receptors to affective disorders. The identification of this family of receptors should rekindle the investigation of the roles of trace amines in mammalian nervous systems and may potentially lead to the development of novel therapeutics for a variety of indications.

Tryptamine, serotonin and catecholamines: an immunocytochemical study in the central nervous system

Tryptamine, a serotonin-related indolamine, could be involved in the modulation of catecholaminergic and serotoninergic systems interaction. Despite previous reports on this topic, the morphological relationship among these systems is not well described. We studied the interaction among serotoninergic and catecholaminergic with tryptaminergic systems by double immunostaining at the level of light microscopy. Mesencephalic rat brain sections treated according to the Schiff quenching method were double immunostained using peroxidase and fluorescein labeled antibodies. Primary antibodies to anti-tryptophan hydroxylase (TrpOH), anit-tyrosine hydroxylase (TH) and anti-tryptamine (T) were used to demonstrate serotoninergic, catecholaminergic and tryptaminergic neurons respectively. A morphometric study was performed in order to analyze the different morphological characteristics of each system. The results showed that (i) T+ and TrpOH+ neurons are localized in the same areas but their morphology is significantly different. Moreover morphometric parameters of T+ neurons were significantly different from those TrpOH+ or TH+ neurons; (ii) The number of TrpOH+ neurons was larger than T+ neurons; (iii) T+ neurons were dominant in the lateral dorsal raphe nucleus. TrpOH+ neurons were more numerous in the central area of the dorsal raphe nucleus; (iv) Coexpression of TrpOH and T was demonstrated in the somata of dorsal raphe nucleus neurons; (v) TrpOH+ neurons from raphe nuclei and TH+ neurons from substantia nigra are contacted by T+ fibres. The present morphological evidence supports a functional relationship among these three aminergic systems.

A high-affinity [3H]tryptamine binding site in human brain

In vitro filtration binding revealed high-affinity specific [3H]tryptamine binding sites in human brain. These binding sites are heterogeneously distributed throughout brain, ranging from 280 fmol/mg protein in hippocampus and thalamus to approximately 90 fmol/mg protein in medulla oblongata and cerebellum. Preliminary autoradiographic studies indicate a heterogeneous distribution within layers of the frontal cortex. The observed stereoselectivity of the site, the interaction of the site with a G protein and the observed region-selective downregulation of the site in a human pathological condition, i.e. hepatic encephalopathy (Mousseau et al., 1994), suggests that this binding site is a functional [3H]tryptamine receptor. A similarity in kinetics and distribution of the [3H]tryptamine receptor in human and rat brain indicates that these two entities represent homologous structures, although the difference in pharmacological profiles suggests species variants. One cannot exclude the possibility that the rat and human [3H]tryptamine receptors do represent distinct subtypes. Finally, the suggested role for tryptamine in neuropsychiatric disorders as originally suggested by Dewhurst (1968) is supported by the present series of experiments.

Effects of low- and high-dose tranylcypromine on [3H]tryptamine binding sites in the rat hippocampus and striatum

Chronic studies were initiated in rats to determine the effects of high- and low-dose tranylcypromine (TCP) on [3H]tryptamine (3H-T) binding sites. Male Sprague-Dawley rats were administered TCP (0.5 or 2.5 mg/kg/day) or vehicle (distilled water) for 4, 10 or 28 days via Alzet minipumps. After decapitation, the hippocampus and striatum were used to prepare membrane fragments for single point 3H-T binding. Hippocampal 3H-T binding was reduced after 10 and 28 days with the low dose and after 4, 10 and 28 days with the high dose. Striatal 3H-T binding was reduced by both doses at all time intervals. The high dose resulted in a significantly greater reduction in striatal 3H-T binding than did the low-dose after 4, 10, and 28 days. These results suggest that a more rapid reduction of 3H-T binding in the hippocampus and/or a greater reduction of 3H-T binding in the striatum by high-dose TCP than by low-dose TCP may be contributing factors in the reported efficacy of the former in refractory depression.

Urinary excretion of bioactive amines and their metabolites in psychiatric patients receiving phenelzine

Phenelzine [2-phenylethylhydrazine] (PLZ), a potent inhibitor of monoamine oxidase (MAO)-A and -B, is used widely in psychiatry. We have studied the effects of PLZ administration on urinary excretion of several bioactive amines and their metabolites in psychiatric patients. Urine samples (24-hour) were collected prior to treatment and again at 2 and 4 weeks of treatment with PLZ (30-90 mg daily in divided doses). Amines and metabolites analyzed included 2-phenylethylamine (PEA), m- and p-tyramine (m- and p-TA), phenylacetic acid (PAA), m- and p-hydroxyphenylacetic acid (m- and p-OH-PAA), tryptamine (T), 5-hydroxytryptamine (5-HT), 5-hydroxyindoleacetic acid (5-HIAA), normetanephrine (NME), 3-methoxy-4-hydroxyphenylglycol (MHPG), 3-methoxytyramine (3-MT), and homovanillic acid (HVA). Levels of PEA, p-TA, 5-HT, and T were elevated during treatment with PLZ, but no significant changes in urinary excretion of the acid metabolites PAA, p-OH-PAA, and 5-HIAA were observed. Urinary levels of the noradrenaline metabolites NME and MHPG were increased and decreased, respectively; a similar pattern was observed with the dopamine metabolites 3-MT and HVA. There was an elevation in levels of m-TA and a decrease in its acid metabolite m-OH-PAA during the treatment with PLZ.

Tryptamine: a metabolite of tryptophan implicated in various neuropsychiatric disorders

Although early interest in the biomedical relevance of tryptamine has waned in recent years, it is clear from the above discussion that the study of tryptamine is worthy of serious consideration as a factor in neuropsychiatric disorders. The study of [3H]-tryptamine binding sites indicates an adaptive responsiveness characteristic of functional receptors. The question raised by Jones (1982d) on whether tryptamine is acting centrally as a neurotransmitter or a neuromodulator still remains mostly unanswered, although the evidence cited within this review strongly suggests a modulatory role for this neuroactive amine (see also Juorio and Paterson, 1990). The synthesis and degradative pathways of tryptamine, as well as the intricate neurochemical and behavioral consequences of altering these pathways, are now more fully understood. It is not yet clear what the role of tryptamine is under normal physiological [homeostatic] conditions, however, its role during pathological conditions such as mental and physical stress, hepatic dysfunction and other disorders of metabolism (i.e. electrolyte imbalance, increased precursor availability, enzyme induction or alterations in enzyme co-factor availability) may be quite subtle, perhaps accounting for various sequelae hitherto considered idiopathic. The evidence for a primary role for tryptamine in the etiology of mental or neurological diseases is still relatively poor, although the observations that endogenous concentrations of tryptamine are particularly susceptible to pharmacological as well as physiological manipulations serve to reinforce the proposition that this indoleamine is not simply a metabolic accident but rather a neuroactive compound in its own right. Finally, one might wonder what proportion of the data attributed to modifications of 5-HT metabolism might, in fact, involve unrecognized changes in the concentrations of other neuroactive metabolites of tryptophan such as tryptamine.

Effects of age and of chronic antidepressant treatment on [3H]tryptamine and [3H]dihydroalprenolol binding to rat cortical membranes

1. The effects of age and of chronic antidepressant treatment on [3H]tryptamine and [3H]dihydroalprenolol binding site density were measured in brain cortical membranes from male Sprague-Dawley rats. 2. The density but not the affinity of [3H]tryptamine binding sites was increased in 18-month-old rats relative to 3-month-old rats. Neither the density nor the affinity of [3H]dihydroalprenolol binding sites was affected by age. 3. Chronic administration (28 days s.c. via Alzet osmotic minipumps) of tricyclic antidepressant drugs (daily doses: imipramine.HCl, 30 mg kg-1; desipramine.HCl, 10 mg kg-1; clomipramine.HCl, 10 mg kg-1) resulted in decreases in [3H]dihydroalprenolol binding site density but no changes in [3H]tryptamine binding site density; no changes in affinity of either site were observed. 4. Chronic administration (s.c. via Alzet osmotic minipumps) of monoamine oxidase inhibitor antidepressant drugs (daily doses: tranylcypromine.HCl, 0.5 and 1.0 mg kg-1; phenelzine sulfate, 5 and 10 mg kg-1, each for 28 days; clorgyline.HCl, 1.0 mg kg-1; (-)-deprenyl.HCl, 1.0 mg kg-1, each for 14 days) resulted in decreases in [3H]tryptamine binding site density, without any effects on the affinity of this site. In addition, each of these monoamine oxidase inhibitors except (-)-deprenyl resulted in a decrease in [3H]dihydroalprenolol binding site density. No affinity changes were observed. 5. These data indicate that the [3H]tryptamine binding site exhibits physiological changes with aging and is differentially sensitive to the actions of tricyclic antidepressants and monoamine oxidase inhibitor antidepressants, respectively.

Functional interactions of 2-phenylethylamine and of tryptamine with brain catecholamines: implications for psychotherapeutic drug action

1. The relevance of trace amine research is outlined for PEA and T in the context of psychotherapeutic drug action, particularly in relation to the actions of MAO-inhibitor antidepressant drugs. 2. Evidence for the neuronal localization of these amines and their relationship to brain catecholamines is discussed with respect to possible co-localization with DA and their distribution within the nigro-striatal/striato-nigral system. 3. The results of recent experiments assessing the behavioural effects of prodrugs for PEA and T are described. The interactions of these compounds with MAO inhibitors are assessed and the actions of PEA prodrugs are discussed in relation to brain DA systems. 4. Recent evidence for functional decreases in beta-adrenergic receptors following chronic administration of MAO inhibitors is outlined. The lack of association of such effects with the percentage of MAO inhibition observed after these treatments indicates influences of these compounds (or metabolites) on factors other than MAO activity as mediators of these effects. The possible role of PEA (as a metabolite of PLZ) in this context is proposed. The possible involvement of PEA in emergent changes in beta-adrenergic receptors induced by chronic antidepressant drugs is hypothesized in relation to ongoing research.

Analysis of tryptamine at the femtomole level in tissue using negative ion chemical ionization gas chromatography-mass spectrometry

An ultra sensitive method for the detection of tryptamine, an endogenous amine in mammalian neuronal systems, at the femtomole level has been developed using negative chemical ionization gas chromatography-mass spectrometry (NCI-GC-MS). The amine is converted into a perfluorinated spirocyclic derivative, e.g. 1-pentafluoro-2-methylenepyrrolidine-3-spiro-3'-(3H-indole) which is detected using selected-ion monitoring of the (M-2HF) ions of the endogenous and deuterated internal standard compounds. Two mass spectrometers were compared; they gave minimum detectable quantities from tissue samples of 40 pg (VG-7070F) and 0.9 pg (VG-70S) respectively. These detection levels are approximately 5-200 times lower than have been obtained by previous MS methods.

Neurochemical changes in rat brain amines after short- and long-term inhibition of monoamine oxidase by a low dose of tranylcypromine

The effects of short- and long-term administration of a low dose of tranylcypromine on brain and urine levels of several biogenic amines and on brain activity of monoamine oxidases (MAO) A and B were investigated. MAO-A and MAO-B were inhibited by greater than 85% on day 1, and this inhibition continued to increase over the course of the study (42 days). Levels of 5-hydroxytryptamine in brain continued to increase up to day 21 and did not decline from day 21 to day 42, and levels of tranylcypromine itself continued to increase up to day 42. Dopamine concentrations peaked at day 10 and were not significantly different from that value by day 42. Brain levels of tryptamine and beta-phenylethylamine showed dramatic elevations after the first dose of the drug and remained essentially unchanged from those high values throughout the course of the drug treatment. Brain and urine increases in tryptamine and beta-phenylethylamine showed similar patterns, whereas urinary 5-hydroxytryptamine excretion reached maximal levels earlier than did brain levels.

Neuropharmacological and neurochemical properties of N-(2-cyanoethyl)-2-phenylethylamine, a prodrug of 2-phenylethylamine

1 N-(2-cyanoethyl)-2-phenylethylamine (CEPEA) was examined as a possible prodrug of 2-phenylethylamine (PEA). 2 Pharmacokinetics of PEA and CEPEA were investigated in rat brain, blood and liver by gas chromatography with electron-capture detection (GC-ECD). Interactions of PEA and CEPEA with putative neurotransmitter amines were investigated by use of high performance liquid chromatography with electrochemical detection (h.p.l.c.-e.c.). 3 Administration of PEA caused transient increases in PEA concentrations which decreased rapidly in brain and blood and at a slower rate in liver. Administration of CEPEA caused sustained elevations of PEA concentrations and elimination of PEA was markedly decreased in these tissues relative to the situation after administration of PEA itself. 4 Administration of CEPEA caused more prolonged decreases in brain noradrenaline, dopamine and 5-hydroxytryptamine concentrations than those observed after PEA administration, although values increased to control levels eventually.

Neurochemical and neuropharmacological properties of 4-fluorotranylcypromine

1. The 4-fluoro analogue of the monoamine oxidase-inhibiting antidepressant tranylcypromine was compared to the parent drug with regard to the following: inhibition of monoamine oxidases A and B in vitro and ex vivo; levels of both drugs in brain, liver, and blood after injection of equimolar doses; and effects on brain levels of the amines 2-phenylethylamine, tryptamine, norepinephrine, dopamine, and 5-hydroxytryptamine. 2. 4-Fluorotranylcypromine was found to be 10 times more potent than tranylcypromine at inhibiting monoamine oxidases A and B in vitro in rat brain homogenates. 3. After administration (0.1 mmol/kg, ip), 4-fluorotranylcypromine attained higher brain and liver levels and provided greater availability than did tranylcypromine after the injection of an equimolar amount. 4. At the dose employed, the ex vivo monoamine oxidases A and B inhibitory profiles in brain and liver over a 24-hr period following tranylcypromine and 4-fluorotranylcypromine treatment were not different from each other. 5. Although the drugs had similar effects on inhibition of brain MAO ex vivo, they differed from one another at several time intervals in the increases in concentrations of 2-phenylethylamine, tryptamine, norepinephrine, dopamine, and 5-hydroxytryptamine produced in brain. 6. In conclusion, fluorination of tranylcypromine in the 4 position of the phenyl ring produced a drug which was more potent than the parent drug at inhibiting MAO in vitro and attained higher levels in brain than did tranylcypromine itself after intraperitoneal injection of equimolar amounts of the drugs. 4-Fluorotranylcypromine increased the concentrations of trace amines, catecholamines, and 5-hydroxytryptamine in brain at most time intervals following intraperitoneal injection, and at some time intervals there were differences from tranylcypromine with regard to the amine concentrations produced.

Pharmacological analysis of the variation in behavioural responses to tryptamine in five strains of mice

The effects of tryptamine on behaviour were studied in five strains of mice. There were significant strain differences in the intensity of the 5-HT syndrome (head weaving and hindlimb abduction) and head twitch responses. The intensity of the 5-HT syndrome correlated significantly with the brain tryptamine content, although the occurrence of head twitch was unrelated. The 5-HT2 receptor antagonist, ketanserin, antagonized the head twitch responses elicited by tryptamine without affecting the head weaving or hindlimb abduction. Metergoline, an antagonist of both the 5-HT1 and 5-HT2 receptors, strongly inhibited both the 5-HT syndrome and the head twitch responses in all five strains. [3H]5-HT and [3H]ketanserin binding in the frontal cortex of the five strains of mice was also studied. The number of [3H]5-HT binding sites did not differ among the five strains of mice although there was a noticeable difference in the number of [3H]ketanserin binding sites. These results suggest that the 5-HT syndrome and the head twitch responses induced by tryptamine are linked separately with the 5-HT1 and 5-HT2 receptors, respectively. The strain differences in the tryptamine-induced 5-HT syndrome can be explained by the different levels of brain tryptamine. The differences in the head twitch responses in the mice are probably derived from the differences in the 5-HT2 receptor binding sites in the brain and the content of brain tryptamine.

N,N-dipropargyl-2-phenylethylamine, a potential prodrug of 2-phenylethylamine: neurochemical and neuropharmacological studies in rat

An evaluation of N,N-dipropargyl-2-phenylethylamine (DPGPEA) as a prodrug to increase brain levels of 2-phenylethylamine (PEA) was conducted in rats. A 0.1 mmol/kg (IP) dose of DPGPEA was administered and produced marked elevations of PEA levels in brain, liver and blood which were sustained for several hours. Ex vivo MAO inhibition data indicated DPGPEA to be an inhibitor of MAO-B, although the effect was much weaker than seen with tranylcypromine or pargyline. DPGPEA caused brain noradrenaline, dopamine and 3,4-dihydroxyphenylacetic acid levels to temporarily decrease significantly below controls. Concomitant increases in homovanillic acid and 5-hydroxyindole-3-acetic acid levels suggest that the PEA or N-propargylPEA formed and/or DPGPEA itself have significant effects on release and reuptake of neurotransmitters. DPGPEA was also shown to be metabolized to N-propargyl-PEA, another prodrug of PEA, in vivo.

Tryptamine receptors: fact, myth or misunderstanding?

Tryptamine is an endogenous brain amine which is implicated in neural regulation and proposed to play a significant role in the aetiology of some neuropsychiatric illnesses. Recent reports indicate the possible existence of specific tryptamine binding sites. It has been postulated that these binding sites may be functional tryptamine receptors in the central nervous system. The status of current developments in this area is critically reviewed. Current problems are outlined and discussed in terms of the specificity of the [3H]-tryptamine binding site and its functional assessment with experiments involving both drug treatment and electrolytic and neurotoxin-induced brain lesions. Current data indicate that the [3H]-tryptamine binding site is selective and not attributable to residual monoamine oxidase binding.

N-(3-chloropropyl)phenylethylamine as a possible prodrug of beta-phenylethylamine: studies in the rat brain

N-(3-Chloropropyl)phenylethylamine (CPPEA) was examined as a possible prodrug of the neuromodulator trace amine beta-phenylethylamine (PEA) in rat tissues. CPPEA produced sustained elevation of PEA levels in rat brain, blood and liver. Rat brain concentrations of noradrenaline, dopamine and 5-hydroxytryptamine were decreased by administration of CPPEA.

Rapid analysis of beta-phenylethylamine in tissues and body fluids utilizing pentafluorobenzoylation followed by electron-capture gas chromatography

A rapid, sensitive gas chromatographic procedure for analysis of beta-phenylethylamine is reported. The procedure involves extraction with a liquid ion-pairing compound, back-extraction with HCl, basification and reaction with pentafluorobenzoyl chloride under aqueous conditions. The pentafluorobenzoyl derivative of beta-phenylethylamine is then separated and analyzed on a gas chromatograph equipped with a capillary column and an electron-capture detector. The procedure produces a derivative which has good chromatographic properties and a high degree of stability. The method has been applied to analysis of beta-phenylethylamine in a variety of tissues and body fluids.

The behavioural effects of intravenously administered tryptamine in mice

The behavioural effects of intravenously administered tryptamine were examined in mice. Tryptamine in a dose greater than 15 mg/kg induced distinct head-weaving and hindlimb abduction. These behavioural syndromes appeared immediately after the injection and disappeared within 3 min. The changes in time course of the behaviour induced by tryptamine were consistent with those of the levels of tryptamine in the brain. Pretreatment with p-chlorophenylalanine, a depleter of 5-hydroxytryptamine (5-HT), failed to alter the effects of tryptamine on head-weaving or hindlimb abduction but did result in head-twitches which were never seen after tryptamine alone. Metergoline strongly antagonized the behavior induced by tryptamine. Pirenperone and haloperidol inhibited the behavioural syndrome, antagonizing the head-weaving in particular. alpha-Methyl-p-tyrosine, a depleter of dopamine, reduced the head-weaving without affecting the hindlimb abduction. These results indicate that the 5-HT syndrome induced by intravenous administration of tryptamine is due to the direct effect of tryptamine on the 5-HT receptor. Tryptamine-induced behaviour, especially head-weaving, seems to be linked with dopaminergic neurones.

Tryptamine enhancement of neurotransmitter release under conditions that normally depress calcium influx

Neurotransmitter release, resulting in excitatory and inhibitory junction potentials (E- and IJPs) is normally mediated by an influx of calcium ions into nerve terminals following depolarization. At a lobster neuromuscular junction, tryptamine is shown to greatly enhance the amplitude and duration of evoked E- and IJPs in low Ca2+-high Mg2+ media that depress Ca2+ influx. This suggests that in the presence of tryptamine, intracellular Ca2+ sources may support evoked, phasic neurotransmitter release.

Analysis of the cardiovascular responses to central injection of tryptamine in rats

Tryptamine (2-20 micrograms), administered into the lateral cerebral ventricle of the rat, evoked a pressor response which was sometimes followed by a prolonged depressor response. The intracisternal administration of tryptamine (7-20 micrograms) caused a slow progressive and long-lasting depressor effect without or with an initial pressor effect. The pressor response was accompanied by variable changes in heart rate, whilst the pure depressor response was accompanied by a decrease in heart rate. After transection of the spinal cord between C1 and C2 the pressor response was substantially reduced or abolished. Methysergide, injected centrally, antagonized in a dose-dependent manner the pressor effect, whilst p-chlorophenylalanine, atropine and hexamethonium, administered by the same route, did not diminish this effect. It is concluded that tryptamine, injected centrally, causes both increases and decreases in arterial blood pressure and heart rate. The pressor response to tryptamine results from the activation of central noncholinergic, methysergide-sensitive, receptor sites and the depressor response to tryptamine may be due to a centrally-induced reduction in sympathetic nervous activity. It is tentatively suggested that tryptamine, like 5-hydroxytryptamine, participates in the physiological regulation of the cardiovascular system of the rat, as both a central excitatory and inhibitory regulator.

Comparative ontogenesis of brain tryptamine, serotonin, and tryptophan

The pattern of ontogenetic development of tryptophan (TP), tryptamine (T), indole-3-acetic acid (IAA), 5-hydroxytryptamine (5-HT; serotonin), and 5-hydroxyindole-3-acetic acid (5-HIAA) in the brains of rats aged 1-45 days is presented. Analysis of the five components in each brain allows the calculation of the acid/amine and amine/amino acid ratios. These metabolic indexes are a useful tool to study and compare the metabolic origins and fates of both amines. The ontogenetic patterns of TP, T, and IAA are very similar, especially during the first week postpartum. The highest and lowest levels found for T were 2.2 ng/g and 0.1 ng/g at the 1st and 5th day, respectively. The temporal relationship between the T/TP and IAA/T ratios suggests the existence of mechanisms protecting T against monoamine oxidase (MAO) which develop in parallel to synaptogenesis. Significant correlations were found between TP and IAA during the whole period studied and between TP and T during the first week after birth. The 5-HT peak found during the first postpartum week could be due to a non-neuronal pool of 5-HT protected against MAO and possibly contained in mast cells. Preliminary determinations on leptomeningeal membranes suggest the existence of such a pool.

Brain levels of 5-hydroxytryptamine, tryptamine and 2-phenylethylamine in the rat after administration of N-cyanoethyltranylcypromine

Brain levels of 5-hydroxytryptamine (5-HT), tryptamine (T), 2-phenylethylamine (PEA) and monoamine oxidase activity at 5, 15, 30, 60, 120 and 240 min were determined in male Sprague-Dawley rats after intraperitoneal injection of the "pro-drug" N-2-cyanoethyltranylcypromine (CE-TCP, dose 0.1 mMole/kg). Analyses of 5-HT, T and PEA were performed on an electron-capture gas chromatograph with a capillary column. Activity of MAO-A and MAO-B was measured using a radiochemical method. Results indicate substantial inhibition of MAO in rat brain after intraperitoneal administration of CE-TCP, leading to elevated levels of 5-HT, T and PEA as early as 5 min after drug administration. Increases in brain levels of the trace amines T and PEA were much greater (approximately 40 and 100 times control levels, respectively) than with 5-HT (approximately 1.8 times control level) 240 min after administration of CE-TCP.

Determination of endogeneous indoleacetic acid and tryptophol in mouse brain by high performance liquid chromatography with fluorometric detection

A simple and sensitive method using high performance liquid chromatography with fluorometric detection has been developed for the identification and quantitation of the endogeneous tryptamine metabolites, indoleacetic acid (IAA) and tryptophol (TOL) in the normal mouse brain. The limits of sensitivity are 5pg for both IAA and TOL. The extract procedure from the brain is only to deproteinize samples. The mean concentrations of IAA and TOL in the mouse brain are 8.99 +/- 0.31 ng/g and 3.56 +/- 0.21 ng/g respectively. The effects of pargyline and tryptamine on the levels of IAA and TOL were also studied.

Tryptamine: a neuromodulator or neurotransmitter in mammalian brain?

Tryptamine synthesized by decarboxylation of L-tryptophan occurs as an endogenous constituent of mammalian brain albeit at very low concentrations (low ng/g range). It is primarily metabolized by oxidative deamination by MAO and possesses an extremely rapid turnover and half-life. Subcellular localization appears to be in nerve terminals and it is releasable by electrical or potassium evoked depolarization. Neuropharmacological and electrophysiological data strongly suggest the existence of post-synaptic receptors for tryptamine independent of those for 5HT. There may exist a rostrally projecting neuronal tryptamine containing system arising from cell bodies in or close to the nucleus raphé medianus. The demonstration of specific receptors for tryptamine in the CNS strongly indicates a transmitter role, although a strong case can be made for a role as a modifier of central 5HT systems. The possibility also exists that 5HT and tryptamine may be mediators of functionally opposite neuronal pathways. Whatever the role of tryptamine in the CNS it is clear that it not simply present as an accident of metabolism or a "biological artefact." The indications are that it possesses important functions in central neurotransmission.

In vivo pharmacological studies on the interactions between tryptamine and 5-hydroxytryptamine

1 Three methods have been used in an attempt to study the interactions of tryptamine with central 5-hydroxytryptamine (5-HT) systems. 2 In grups of mice pretreated with tranylcypromine, tryptamine reduced the number of mice showing head twitches following the 5-HT precursor, 5-hydroxytryptophan. This effect was not seen in mice pretreated with saline and tryptamine itself did not induce head twitches in either group. 3 The swallowing reflex induced by 5-hydroxytryptophan in rats anaesthetized with urethane was substantially reduced by tryptamine injected into the internal carotid artery. This effect was seen in rats pretreated with saline or tranylcypromine, in the latter case the effects being more profound and longer lasting. In addition, swallowing evoked by the 5-HT uptake blocker, fluoxetine, and the 5-HT releaser, p-chloroamphetamine, was also reduced by tryptamine. 4 5-HT or noradrenaline injected intravenously into 5 day-old chicks caused a dose-dependent behavioural depression resembling sleep. Tryptamine at high doses caused behavioural alerting effects. Tryptamine at low doses had no overt effects but enhanced depression induced by 5-HT. At behaviourally excitatory doses tryptamine reduced the duration of the 5-HT depression. Noradrenaline-induced depression was not affected by high or low doses of tryptamine. 5 The results show that tryptamine can have complex actions on 5-HT systems depending on the parameter studied and support the notion that tryptamine may be a controlling factor in 5-HT-mediated transmission.

Effects of tranylcypromine on the concentration of some trace amines in the diencephalon and hippocampus of the rat

Concentrations of 4 trace amines in diencephalon and hippocampus of the rat were measured by integrated-ion-current mass spectrometry after administration of the antidepressant drug, tranylcypromine. Much larger increases were observed for 2-phenylethylamine and tryptamine than for m- and p-tyramine.

Effects of tranylcypromine and pargyline on brain tryptamine

Tranylcypromine produces behavioral excitation while pargyline produces depression. Tranylcypromine increased brain tryptophan which led to an accumulation of tryptamine. The levels of tryptamine after tranylcypromine were found to be 3 times those found after pargyline.